Lead Product(s): NZ-TLR9
Therapeutic Area: Oncology Product Name: NZ-TLR9
Highest Development Status: Preclinical Product Type: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 26, 2021
The collaboration enables LIDDS to expand the manufacturing of new product candidates, e.g. including biomolecules and cytostatics, in addition to the already existing collaboration with Recipharm for Liproca Depot.